A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSCG Cell Therapy Pte. Ltd.
About this trial
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)
Subjects with HCC who have received standard systemic therapies
HLA-A *02
BCLC stage B or C
Disqualifiers
Subjects with history of another primary cancer within 5 years
Central nervous system metastasis and clinically significant central nervous system disease
Previous or current coexistence of hepatic encephalopathy
Currently present with symptomatic third space fluid accumulation
Trial design
Treatments tested in this trial
- SCG101
Treatment groups
38 Participants
are divided into 1 treatment groupLocations
7Beijing100020, BeijingBeijing Municipality, China
Guangzhou510000, GuangzhouGuangdong, China
Zhengzhou450003, ZhengzhouHenan, China
Changchun130000, ChangchunJilin, China
Sponsors and collaborators
SCG Cell Therapy Pte. Ltd.
Lead sponsor
Source ClinicalTrials.gov